- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00841438
Efficacy of Early Administration of Clotinab in Acute Myocardial Infarction (ECLAT-STEMI)
Efficacy of Clotinab in Acute Myocardial Infarction Trial- ST Elevation Myocardial Infarction
Study Overview
Detailed Description
It is well known that platelet-mediated thrombosis is account for the pathophysiology of acute coronary syndrome (ACS) (1,2). In the treatment of ACS, intravenous platelet glycoprotein (GP) IIb/IIIa receptor antagonists for platelet aggregation may reduce the risk of ischemic complications (3-7). Therefore, in the management of ACS, Platelet GP IIb/IIIa receptor inhibitors have been developed as a promising new therapy for the reduction of coronary events and the improvement of clinical outcomes.
Abciximab, one of platelet GP IIb/IIIa receptor blockers, was developed by Coller in 1985 and named as 7E3(8). Abciximab is a chimeric human monoclonal antibody and binds to platelet surface GP IIb/IIIa receptor competitively with adhesive molecules such as fibrinogen and von Willebrand factor, and blocks the final stage of platelet aggregation(9). The effect of Abciximab has been proved in many clinical trials such as the EPIC trial(9), EPILOG trial(10), TARGET(11) etc. The contribution of GP IIb/IIIa inhibition in ACS (Tirofiban) is shown in placebo-controlled trials in which upstream GP IIb/IIIa inhibition was initiated upon admission (12,13). Although these results are encouraging, there are few other data to support the use of upstream GP IIb/IIIa inhibitors. Moreover, according to the GUSTO-IV trial (14), the use of Abciximab was not recommended in the manner of upstream use. To evaluate the role of abciximab in conservatively treated non-ST-elevation ACS patients, the GUSTO-IV study randomized 7800 patients with non-ST-elevation ACS to receive either placebo or an Abciximab bolus (0.25 mg/kg) and 24-hour or 48-hour infusion(0.125 µg/kg/min). However, in fact, a trend was noted for potential harm with the higher abciximab dose. Even subgroup analyses including high-risk troponin-positive patients showed no benefit with either abciximab regimen (9.7% with placebo, 10.2% with 24-hour abciximab, 11.7% with 48-hour abciximab for death or MI at 30 days, P = NS). Because of these results, the majority of patients received abciximab relatively late, at the time of PCI in clinical practices.
However, the ADMIRAL study (3) demonstrated that early administration of abciximab in patients with ST elevation acute myocardial infarction prior to PCI improves clinical outcomes and also no specifically designed randomized study has addressed the issue of early upstream use of GP IIb/IIIa inhibitors in ST elevation acute myocardial infarction who are undergoing PCI, especially in the era of routine pretreatment with 600 mg of clopidogrel. Therefore, the objective of the randomized ECLAT-STEMI study was to assess the hypothesis that the early upstream use of Clotinab is a useful therapy in patients with ST elevation MI undergoing PCI compared to "provisional use", even after pretreatment with a 600-mg loading dose of clopidogrel.
The Clotinab, a product made in ISU ABXIS CO., LTD, was produced by inserting anti- platelet GP IIb/IIIa DNA into Chinese hamster's ovary cell. Since it contains identical active ingredient as ReoPro® on the domestic market, it is expected that the Clotinab has same efficacy to ReoPro® as a platelet GP IIb/IIIa receptor inhibitor. Recently, the Clotinab is shown to be safe and effective in preventing ischemic heart complications for high-risk patients who will undergo PCI.
2. Study Protocol 2-1. Objectives: Randomized, controlled, single blind, multi-center trial To assess the hypothesis that the early upstream use of Clotinab is a useful therapy in patients with ST elevation myocardial infarction undergoing PCI compared to "provisional use", even after pretreatment with a 600-mg loading dose of clopidogrel.
2-2. Study Design: Efficacy of CLotinab in ST-elevation Acute myocardial infarction Trial - ST Elevation Myocardial Infarction (The ECLAT - STEMI study)
2-3. Study Endpoints:
Primary Endpoint: Efficacy To evaluate the effect of early upstream use of Clotinab (started at emergency room) co-administered with clopidogrel loading dose 600mg in STEMI
- 30 Days MACCE (death, MI, TVR, cerebrovascular event)
Secondary Endpoint: Efficacy and Safety To evaluate the safety of early upstream use of Clotinab (started at emergency room) co-administered with clopidogrel loading dose 600mg in STEMI
- TIMI flow at before and after PCI
- Corrected TIMI frame count after PCI
- Procedural success (No reflow incidence)
- MACCE at 9 month
- Major bleeding event (According to TIMI criteria)
- 9 month Angiography Finding
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Cheonan, Korea, Republic of, 330-716
- Dankook University Hospital
-
Cheonju, Korea, Republic of, 561-716
- Chonbuk National University Hospital
-
Daegu, Korea, Republic of, 700-712
- Keimyung University Dongsan Medical Center
-
Daegu, Korea, Republic of, 700-721
- Kyungpook National University Hospital
-
Daegu, Korea, Republic of, 705-717
- Yeungnam University Hospital
-
Daejeon, Korea, Republic of, 301-721
- Chungnam National University Hospital
-
Goyang, Korea, Republic of, 412-270
- Myongji Hospital
-
Goyang, Korea, Republic of, 410-719
- National Health Insurance Corporation Ilsan Hospital
-
Goyang, Korea, Republic of, 410-773
- DongGuk University International Hospital
-
Gwangju, Korea, Republic of, 501-759
- Chonnam National University Hospital
-
Pusan, Korea, Republic of, 602-741
- Pusan National University Hospital
-
Pusan, Korea, Republic of, 614-735
- Inje University Pusan Paik Hospital
-
Pyungchon, Korea, Republic of, 431-070
- Hallym University Sacred Heart Hospital
-
Seongnam, Korea, Republic of, 463-804
- Seoul National University Bundang Hospital
-
Seoul, Korea, Republic of, 135-710
- Samsung Medical Center
-
Seoul, Korea, Republic of, 130-702
- Kyung Hee University Medical Center
-
Seoul, Korea, Republic of, 139-711
- Eulji General Hospital
-
Seoul, Korea, Republic of, 120-752
- Yonsei University
-
Seoul, Korea, Republic of, 134-090
- Kyung Hee University East-West Nea Medical Center
-
Seoul, Korea, Republic of, 135-723
- Yonsei University Youngdong Severance Hospital
-
Seoul, Korea, Republic of, 137-702
- Catholic University of Korea, kangnam St. Mary's Hospital
-
Seoul, Korea, Republic of, 137-708
- Inje University Sanggye Paik Hospital
-
Seoul, Korea, Republic of, 138-737
- Asan Medical Center
-
Seoul, Korea, Republic of, 139-705
- Korea University Anam Hospital
-
Seoul, Korea, Republic of, 150-713
- Catholic University of Korea, St. Mary's Hospital
-
Seoul, Korea, Republic of, 150-951
- Hallym University Kangnam Sacred Heart Hospital
-
Seoul, Korea, Republic of, 405-222
- Gachon University Gil Medical Center
-
Seoul, Korea, Republic of, 82-2-818-6635
- Korea University Guro Hospital
-
Suwon, Korea, Republic of
- Ajou University Hospital
-
Ulsan, Korea, Republic of, 682-714
- Ulsan University Hospital
-
Wonju, Korea, Republic of, 220-702
- Wonju Christian Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient must be at least 18-80 years of age.
- The patient had the symptoms of acute myocardial infarction within 12 hours with ST segment elevation of more than 1 mm in at least two contiguous leads of EKG or new onset LBBB.
- The patient or guardian agrees to the study protocol and provides informed, written consent.
Exclusion Criteria:
- Patients to whom PCI can not be undergone within 12 hours from receiving the study drug
- Cardiogenic shock or symptomatic hypotension or sitting SBP < 95 mmHg
- The history of major surgery, trauma, retinal hemorrhage, significant gastrointestinal or genitourinary bleeding within recent 6 weeks;
- History of cerebrovascular attack within two years, or cerebrovascular attack with a significant residual neurological deficit
- Severe or malignant hypertension (= sitting SBP > 180 mmHg and/or sitting DBP > 105 mmHg)
- The patients who require oral anticoagulants during the trial; patients who have been administrated oral anticoagulants within 7 days
- The history or diagnosis of vasculitis; renal insufficiency (the level of serum creatinine is two times higher than the upper limit of normal of each center)
- The patients who could not take anti-platelet drugs
- The patients who might die of other disease than cardiac disease during the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Provisional use of Clotinab
Provisional use of clotinab
|
Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
Other Names:
|
EXPERIMENTAL: Upstream use of clotinab
early upstream use of clotinab
|
Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
MACCE (death, MI, TVR, cerebrovascular event)
Time Frame: 30 days
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
MACCE (death, MI, TVR, cerebrovascular event)
Time Frame: 9 months
|
9 months
|
TIMI flow at before and after PCI
Time Frame: Immediate post procedure
|
Immediate post procedure
|
Corrected TIMI frame count after PCI
Time Frame: Immediate postprocedure
|
Immediate postprocedure
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ISU-CLT-07001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Infarction
-
Azienda ULSS 5 PolesanaUniversity of PadovaUnknownMyocardial Infarction, Acute | ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Italy
-
University Medical Centre LjubljanaCompletedCardiac Arrest | Postresuscitation Syndrome | Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)Slovenia
-
Fundacio Privada Mon Clinic BarcelonaMiracor Medical SANot yet recruiting
-
Stiftung Institut fuer HerzinfarktforschungGlaxoSmithKline; University Hospital Muenster; Klinikum NürnbergCompletedMyocardial Infarction | ST-Elevation Myocardial Infarction | Non-ST-Elevation Myocardial InfarctionGermany
-
Population Health Research InstituteCanadian Institutes of Health Research (CIHR); Boston Scientific CorporationActive, not recruitingST Elevation Myocardial Infarction | Non ST Elevation Myocardial InfarctionCanada
-
Bispebjerg HospitalOdense University Hospital; Zealand University Hospital; Hvidovre University... and other collaboratorsRecruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Denmark
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom
-
University of LeedsUniversity College, LondonCompletedST-elevation Myocardial Infarction | Non ST-elevation Myocardial Infarction
-
Karolinska InstitutetUppsala University; The Swedish Research CouncilActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionSweden
-
Oslo University HospitalVestre Viken Hospital Trust; University of Oslo; University Hospital of North... and other collaboratorsActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionNorway
Clinical Trials on Clotinab
-
Yonsei UniversityKorean Society of Interventional CardiologyCompletedEfficacy of Combination of IntraCoronary Bolus Abciximab and Aspiration Thrombectomy in STEMI (ICAT)Acute Myocardial InfarctionKorea, Republic of